Original from: genomeweb

AI biotechnology startup Valinor has raised $13 million in seed funding to further develop its multiomics-powered machine learning models to boost clinical trial success rates for drug development.

The round was led by CRV, Harpoon Ventures, Amino Collective, and Pelion Venture Partners, according to Valinor, with additional contributions from "numerous" angel investors, such as Charlie Songhurst, Surya Midha, Axel Ericsson, and Kyle Harrison.

Based in San Francisco and launched this year, Valinor is developing ML models that are trained on matching multiomics and clinical outcome datasets to help drug developers "identify responders earlier, design smarter trials, and uncover new insights from real-world biology," the company stated in a LinkedIn post. 

With the money raised, Valinor said it plans to further expand its proprietary datasets and recruit additional machine learning experts to grow its team. 

"Our models are built to surface meaningful features that underlie patient response," Valinor Founder and CEO Joshua Pacini said in a statement. "We believe this approach will empower our pharmaceutical partners to improve clinical trial success rates, cut R&D costs, and, most importantly, speed the delivery of lifesaving medicines to patients."

Source: Valinor Raises $13M in Seed Funding to Develop Multiomics Platform for Clinical Trial Design